Keyword Analysis & Research: lung cancer drug treatment
Keyword Research: People who searched lung cancer drug treatment also searched
Search Results related to lung cancer drug treatment on Search Engine
-
Sotorasib is First KRAS Inhibitor Approved by FDA - NCI
https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-sotorasib-lung-cancer-kras
WEBJun 25, 2021 · Sotorasib Shrinks Lung Tumors. The CodeBreaK 100 trial, funded by Amgen and NCI, is testing sotorasib (previously called AMG510) as a treatment for people with solid tumors that have KRAS G12C. The mutation, a hallmark of damage from cigarette smoke, is most common in lung cancer.
DA: 92 PA: 74 MOZ Rank: 75
-
Drugs Approved for Lung Cancer - NCI - National Cancer Institute
https://www.cancer.gov/about-cancer/treatment/drugs/lung
WEBUpdated: December 8, 2023. This page lists cancer drugs approved by the Food and Drug Administration (FDA) for lung cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters.
DA: 30 PA: 33 MOZ Rank: 52
-
Lung Cancer Treatment | Johns Hopkins Medicine
https://www.hopkinsmedicine.org/health/conditions-and-diseases/lung-cancer/lung-cancer-treatment
WEBWhat You Need to Know. Treatment for lung cancer varies according to age, type of cancer, extent of disease, tolerance to medication and patient preference. Treatment options include a combination of surgery, radiation, chemotherapy, immunotherapy and targeted therapy. Specific treatment for lung cancer will be determined by your doctor …
DA: 79 PA: 8 MOZ Rank: 74
-
Lung cancer - Diagnosis and treatment - Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/lung-cancer/diagnosis-treatment/drc-20374627
WEBMar 29, 2024 · Treatment. Treatment for lung cancer usually begins with surgery to remove the cancer. If the cancer is very large or has spread to other parts of the body, surgery may not be possible. Treatment might start with medicine and radiation instead. Your healthcare team considers many factors when creating a treatment plan.
DA: 85 PA: 5 MOZ Rank: 9
-
FDA Approves First Targeted Therapy for Lung Cancer Mutation …
https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug
WEBFor Immediate Release: May 28, 2021. Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose ...
DA: 66 PA: 10 MOZ Rank: 69
-
Enhertu Approved for Lung Cancer - NCI - National Cancer Institute
https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-lung-cancer-enhertu-her2
WEBSep 13, 2022 · Now patients with non-small cell lung cancer (NSCLC) have another targeted therapy option. On August 11, the Food and Drug Administration (FDA) gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with NSCLC that has a certain kind of mutation in the HER2 gene (called an “activating” mutation).
DA: 14 PA: 92 MOZ Rank: 9
-
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa2310532
WEBApr 10, 2024 · Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant ...
DA: 67 PA: 35 MOZ Rank: 81
-
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung
https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-subset-non-small-cell-lung-cancer
WEBMay 21, 2021. Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have ...
DA: 41 PA: 23 MOZ Rank: 40
-
Genentech: Press Releases | Thursday, Apr 18, 2024
https://www.gene.com/media/press-releases/15023/2024-04-18/fda-approves-genentechs-alecensa-as-firs
WEBThursday, Apr 18, 2024. FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer. Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell …
DA: 18 PA: 87 MOZ Rank: 61
-
FDA approves tepotinib for metastatic non-small cell lung cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tepotinib-metastatic-non-small-cell-lung-cancer
WEBFeb 15, 2024 · FDA approves tepotinib for metastatic non-small cell lung cancer. On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for ...
DA: 1 PA: 67 MOZ Rank: 8
